Protalex Revenue and Competitors
Estimated Revenue & Valuation
- Protalex's estimated annual revenue is currently $1.4M per year.
- Protalex's estimated revenue per employee is $155,000
Employee Data
- Protalex has 9 Employees.
- Protalex grew their employee count by 0% last year.
Protalex's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Clinical Operations | Reveal Email/Phone |
2 | President | Reveal Email/Phone |
Protalex Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Protalex?
Protalex, Inc. (OTCQB: PRTX) is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating a wide array of autoimmune and inflammatory diseases, including rheumatoid arthritis. Protalex’s lead product, PRTX-100, is derived from bacteria that are known to circumvent aspects of the human immune system. PRTX-100 is a formulation of a proprietary, highly purified form of the Staphylococcal Protein A, which is an immunomodulatory protein produced by Staphylococcus aureus bacteria. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes that mediate inflammation in certain autoimmune diseases. Laboratory studies indicate that the mechanism involves interaction with specific immunologic signaling pathways. Pre-clinical animal studies also demonstrate that very low doses of PRTX-100 have potent therapeutic effects in certain models of immune mediated inflammatory diseases. To date, human clinical studies indicate that PRTX-100 is generally safe and well tolerated at all dose levels evaluated.
keywords:N/AN/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 11 | -8% | N/A |
#2 | $1M | 11 | -65% | N/A |
#3 | $2.3M | 12 | 0% | N/A |
#4 | $2.1M | 16 | -24% | N/A |
#5 | $3.5M | 20 | -49% | N/A |